Exploratory Study of 99mTc-EC20 Imaging for Identifying Patients with Folate Receptor–Positive Solid Tumors
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
UNLABELLED: 99mTc-EC20 is a folate receptor (FR)-targeted imaging agent consisting of the vitamin folate conjugated to 99mTc. FR is expressed on a variety of epithelial cancers, with advanced cancers often expressing FR at significantly higher levels than earlier stages of the disease. The goals of this pilot study were to determine the percentages of various solid tumors that accumulate 99mTc-EC20 in vivo and to correlate 99mTc-EC20 uptake with immunohistochemistry (IHC) analysis of FR expression in available biopsied tumor tissue. METHODS: A total of 154 patients with proven or suspected cancer and at least one lesion of > or =1.5 cm underwent imaging with 99mTc-EC20. The majority of these patients (77%) had a diagnosis of renal cell carcinoma. The remaining patients had a variety of other solid tumors. Whole-body planar images were obtained 1-2 h after injection, followed by SPECT of the region containing index lesions. The uptake of 99mTc-EC20 in tumors was scored as no uptake, mild uptake, or marked uptake. The resultant 99mTc-EC20 data were analyzed for correlation with the expression of the alpha-isoform of FR, as determined by IHC analysis, in tissue available from prior or subsequent surgery or biopsy. RESULTS: The administration of 99mTc-EC20 was well tolerated. Tumors with increased 99mTc-EC20 uptake were identified in 68% of patients, and IHC results were positive for the expression of the alpha-isoform of FR in 67% of patients. The agreement between methods was 61% overall (kappa = 0.096; 95% confidence interval = -0.085 to 0.277), with 72% agreement of positive results and 38% agreement of negative results. CONCLUSION: In vivo imaging with 99mTc-EC20 identified approximately two thirds of patients as having FR-positive tumors. Agreement between imaging and in vitro IHC was poor but was potentially confounded by a lack of correlation between the time of tissue sampling and the time of 99mTc-EC20 imaging, the heterogeneous expression of FR in metastatic lesions from the same patient, and the inability to detect the beta-isoform of FR by IHC. This pilot study of 99mTc-EC20 scintigraphy indicates that the agent is safe and well tolerated and that this noninvasive procedure may have utility in selecting patients likely to benefit from FR-targeted therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Practical Statistics for Medical Research
Altman, D. G. (1990) · doi:10.1201/9780429258589 · Cited by 10,668
Cited by
Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Principles in the design of ligand-targeted cancer therapeutics and imaging agents
Srinivasarao, M., Galliford, C. V., & Low, P. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4519 · Cited by 671
Srinivasarao, M., & Low, P. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00013 · Cited by 605
Exploiting the folate receptor α in oncology
Scaranti, M., Cojocaru, E., Banerjee, S., & Banerji, U. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0339-5 · Cited by 593
Folate-targeted therapeutic and imaging agents for cancer
Low, P. S., & Kularatne, S. A. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.03.022 · Cited by 585
Advances in targeting the folate receptor in the treatment/imaging of cancers
Fernández, M., Javaid, F., & Chudasama, V. (2018) · Chemical Science · doi:10.1039/c7sc04004k · Cited by 539
Utilizing the folate receptor for active targeting of cancer nanotherapeutics
Zwicke, G. L., Ali Mansoori, G., & Jeffery, C. J. (2012) · Nano Reviews · doi:10.3402/nano.v3i0.18496 · Cited by 458
Targeting folate receptor alpha for cancer treatment
Cheung, A., Bax, H. J., Josephs, D. H., Ilieva, K. M., Pellizzari, G., Opzoomer, J., Bloomfield, J., Fittall, M., Grigoriadis, A., Figini, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9651 · Cited by 430
The folate receptor as a rational therapeutic target for personalized cancer treatment
Assaraf, Y. G., Leamon, C. P., & Reddy, J. A. (2014) · Drug Resistance Updates · doi:10.1016/j.drup.2014.10.002 · Cited by 398
Ledermann, J. A., Canevari, S., & Thigpen, T. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv250 · Cited by 347
Visentin, M., Zhao, R., & Goldman, I. D. (2012) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2012.02.002 · Cited by 253
Zhao, R., & Goldman, I. D. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.07.006 · Cited by 190
“For instance, folic acid can be linked to 99Tc to image tumors or sites of inflammation (Fisher et al., 2008).”
An overview of nanoparticles in drug delivery: Properties and applications
Hsu, C.-Y., Rheima, A. M., Kadhim, M. M., Ahmed, N. N., Mohammed, S. H., Abbas, F. H., Abed, Z. T., Mahdi, Z. M., Abbas, Z. S., Hachim, S. K., et al. (2023) · South African Journal of Chemical Engineering · doi:10.1016/j.sajce.2023.08.009 · Cited by 165
GPI Transamidase and GPI anchored proteins: Oncogenes and biomarkers for cancer
Gamage, D. G., & Hendrickson, T. L. (2013) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2013.831024 · Cited by 63
“During the last two decades, folate-based radio-conjugates have been developed to use in PET and SPECT imaging and tested in clinical trials in patients with folate receptor positive solid tumors (Fisher et al., 2008; Siegel et al., 2003).”
BackgroundTargeted delivery of platinum-taxane combination therapy in ovarian cancer
Desale, S. S., Soni, K. S., Romanova, S., Cohen, S. M., & Bronich, T. K. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.09.007 · Cited by 61
Metadata
- Authors
- Fisher, R. E., Siegel, B. A., Edell, S. L., Oyesiku, N. M., Morgenstern, D. E., Messmann, R. A., & Amato, R. J.
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2008-05-15
- Volume
- 49
- Issue
- 6
- Pages
- 899-906
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2140403679
- Cited by
- 143
- References
- 1
- FWCI
- 3.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.